Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1681/ASN.2006050445. Epub 2007 Apr 4.
Affiliations
- PMID: 17409317
- DOI: 10.1681/ASN.2006050445
Randomized Controlled Trial
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
Wouter B A Eijkelkamp et al. J Am Soc Nephrol. 2007 May.
Abstract
Albuminuria reduction could be renoprotective in hypertensive patients with diabetic nephropathy. However, the current use of renin-angiotensin-system intervention is targeted to BP only. Therefore, this study investigated the adequacy of this approach in 1428 patients with hypertension and diabetic nephropathy from the placebo-controlled Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) study. Investigated were the extent of discordance in treatment effects on systolic BP (SBP) and albuminuria and its association with renal outcome in a multivariate Cox model. Among patients with a reduced SBP during treatment, a lack of albuminuria reduction was observed in 37, 26, and 51% (total, losartan, and placebo, respectively) at month 6. SBP or albuminuria reduction was associated with a lower risk for ESRD, whereas combined SBP and albuminuria reduction was associated with the lowest risk for events. Across all categories of SBP change, a progressively lower ESRD hazard ratio was observed with a larger albuminuria reduction. A lower residual level of albuminuria was also associated with lower ESRD risk. In conclusion, changes in albuminuria are not concordant in a substantial proportion of patients when titrated for BP. Meanwhile, the ESRD risk showed a clear dependence on albuminuria reduction. The ESRD risk also showed dependence on the residual level of albuminuria, even in patients who reached the current SBP target. Antihypertensive treatment that is aimed at improving renal outcomes in patients with diabetic nephropathy may therefore require a dual strategy, targeting both SBP and albuminuria reduction.
Comment in
- Albuminuria reduction and nephropathy progression.
Bakris GL. Bakris GL. Curr Hypertens Rep. 2008 Oct;10(5):388-9. Curr Hypertens Rep. 2008. PMID: 18775117 No abstract available.
Similar articles
- Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group. Bakris GL, et al. Arch Intern Med. 2003 Jul 14;163(13):1555-65. doi: 10.1001/archinte.163.13.1555. Arch Intern Med. 2003. PMID: 12860578 Clinical Trial. - Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. de Zeeuw D, et al. Kidney Int. 2004 Jun;65(6):2309-20. doi: 10.1111/j.1523-1755.2004.00653.x. Kidney Int. 2004. PMID: 15149345 Clinical Trial. - Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.
Egan B, Gleim G, Panish J. Egan B, et al. Curr Med Res Opin. 2004 Dec;20(12):1909-17. doi: 10.1185/030079904X13040. Curr Med Res Opin. 2004. PMID: 15701209 Clinical Trial. - Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study. Keane WF, et al. Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. doi: 10.1053/ajkd.2003.50078. Am J Kidney Dis. 2003. PMID: 12612946 Review. - Advances in the treatment of diabetic renal disease: focus on losartan.
Rayner B. Rayner B. Curr Med Res Opin. 2004 Mar;20(3):333-40. doi: 10.1185/030079903125003107. Curr Med Res Opin. 2004. PMID: 15025842 Review.
Cited by
- Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions.
Jha R, Lopez-Trevino S, Kankanamalage HR, Jha JC. Jha R, et al. Biomedicines. 2024 May 15;12(5):1098. doi: 10.3390/biomedicines12051098. Biomedicines. 2024. PMID: 38791060 Free PMC article. Review. - Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease.
Natale P, Palmer SC, Navaneethan SD, Craig JC, Strippoli GF. Natale P, et al. Cochrane Database Syst Rev. 2024 Apr 29;4(4):CD006257. doi: 10.1002/14651858.CD006257.pub2. Cochrane Database Syst Rev. 2024. PMID: 38682786 - Non-invasive chronic kidney disease risk stratification tool derived from retina-based deep learning and clinical factors.
Joo YS, Rim TH, Koh HB, Yi J, Kim H, Lee G, Kim YA, Kang SW, Kim SS, Park JT. Joo YS, et al. NPJ Digit Med. 2023 Jun 17;6(1):114. doi: 10.1038/s41746-023-00860-5. NPJ Digit Med. 2023. PMID: 37330576 Free PMC article. - Consensus Statements from the Diabetologists & Endocrinologists Alliance for the Management of People with Hypertension and Type 2 Diabetes Mellitus.
Tong PC, Chan SC, Chan WB, Ho KK, Leung GT, Lo SH, Mak GY, Tse TS. Tong PC, et al. J Clin Med. 2023 May 11;12(10):3403. doi: 10.3390/jcm12103403. J Clin Med. 2023. PMID: 37240509 Free PMC article. Review. - The Growing Challenge of Chronic Kidney Disease: An Overview of Current Knowledge.
Borg R, Carlson N, Søndergaard J, Persson F. Borg R, et al. Int J Nephrol. 2023 Mar 1;2023:9609266. doi: 10.1155/2023/9609266. eCollection 2023. Int J Nephrol. 2023. PMID: 36908289 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical